| High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors S Maleki Vareki Journal for immunotherapy of cancer 6 (1), 157, 2018 | 450 | 2018 |
| Biomarkers of response to PD-1/PD-L1 inhibition S Maleki Vareki, C Garrigós, I Duran Critical reviews in oncology/hematology 116, 116-124, 2017 | 316 | 2017 |
| TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding PS Petrova, NN Viller, M Wong, X Pang, GHY Lin, K Dodge, V Chai, ... Clinical Cancer Research 23 (4), 1068-1079, 2017 | 263 | 2017 |
| Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors-a systematic review and meta-analysis S Hussaini, R Chehade, RG Boldt, J Raphael, P Blanchette, ... Cancer Treatment Reviews, 2020 | 239 | 2020 |
| COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo KY Salim, S Maleki Vareki, WR Danter, J Koropatnick Oncotarget 7 (27), 41363, 2016 | 145 | 2016 |
| The microbiome and genitourinary cancer: a collaborative review MC Markowski, SA Boorjian, JP Burton, NM Hahn, MA Ingersoll, ... European Urology 75 (4), 637-646, 2019 | 137 | 2019 |
| Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV-counterparts that has implications for immunotherapy SF Gameiro, F Ghasemi, JW Barrett, J Koropatnick, AC Nichols, ... Oncoimmunology 7 (10), e1498439, 2018 | 136 | 2018 |
| CD1d‐independent activation of mouse and human iNKT cells by bacterial superantigens JL Hayworth, DM Mazzuca, S Maleki Vareki, I Welch, JK McCormick, ... Immunology and cell biology 90 (7), 699-709, 2012 | 62 | 2012 |
| Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 58 | 2023 |
| Indoleamine 2, 3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin S Maleki Vareki, M Rytelewski, R Figueredo, D Chen, PJ Ferguson, ... Oncotarget 5 (9), 2778, 2014 | 51 | 2014 |
| Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges M Krishnamoorthy, JG Lenehan, S Maleki Vareki JNCI: Journal of the National Cancer Institute 113 (7), 823-832, 2021 | 44 | 2021 |
| Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy M Krishnamoorthy, L Gerhardt, S Maleki Vareki Cells 10 (5), 1170, 2021 | 44 | 2021 |
| IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells S Maleki Vareki, D Chen, C Di Cresce, PJ Ferguson, R Figueredo, ... PloS one 10 (11), e0143435, 2015 | 43 | 2015 |
| BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma BW Labadie, P Liu, R Bao, M Crist, R Fernandes, L Ferreira, S Graupner, ... Journal of translational medicine 17 (1), 386, 2019 | 38 | 2019 |
| Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines S Maleki Vareki, KY Salim, WR Danter, J Koropatnick PLoS One 13 (1), e0191766, 2018 | 38 | 2018 |
| BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis M Rytelewski, JG Tong, A Buensuceso, HS Leong, S Maleki Vareki, ... Molecular oncology 8 (8), 1429-1440, 2014 | 38 | 2014 |
| The effect of the gut microbiota on systemic and anti-tumor immunity and response to systemic therapy against cancer A Aghamajidi, S Maleki Vareki Cancers 14 (15), 3563, 2022 | 28 | 2022 |
| COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway KY Salim, S Maleki Vareki, WR Danter, J Koropatnick European Journal of Cancer 69, S19, 2016 | 26 | 2016 |
| CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity F Alotaibi, M Rytelewski, R Figueredo, R Zareardalan, M Zhang, ... European journal of immunology 50 (5), 695-704, 2020 | 25 | 2020 |
| T Lymphocyte–Based Cancer Immunotherapeutics AE Borrie, S Maleki Vareki International review of cell and molecular biology 341, 201-276, 2018 | 25 | 2018 |
Jeremy P. BurtonLawson Health Research Institute, Schulich, Surgery, Microbiology & Immunology, uwoVerified email at uwo.ca
